Sandbox:Hamid: Difference between revisions

Jump to navigation Jump to search
Line 13: Line 13:
*In [year], [scientist] was the first to discover the association between [risk factor] and the development of [disease name].
*In [year], [scientist] was the first to discover the association between [risk factor] and the development of [disease name].
*In [year], [gene] mutations were first implicated in the pathogenesis of [disease name].
*In [year], [gene] mutations were first implicated in the pathogenesis of [disease name].
==Classification==
*There is no established system for the classification of [disease name].
OR
*[Disease name] may be classified according to [classification method] into [number] subtypes/groups:
**[Group1]
**[Group2]
**[Group3]
**[Group4]
OR
*[Disease name] may be classified into [large number > 6] subtypes based on:
**[Classification method 1]
**[Classification method 2]
**[Classification method 3]
*[Disease name] may be classified into several subtypes based on:
**[Classification method 1]
**[Classification method 2]
**[Classification method 3]
OR
*Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
OR
*If the staging system involves specific and characteristic findings and features:
*According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
OR
*The staging of [malignancy name] is based on the [staging system].
OR
*There is no established system for the staging of [malignancy name].


==Epidemiology and Demographics==
==Epidemiology and Demographics==

Revision as of 19:12, 13 December 2017


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Hamid Qazi, MD, BSc [2]

Overview

Historical Perspective

Discovery

  • [Disease name] was first discovered by [name of scientist], a [nationality + occupation], in [year]/during/following [event].
  • The association between [important risk factor/cause] and [disease name] was made in/during [year/event].
  • In [year], [scientist] was the first to discover the association between [risk factor] and the development of [disease name].
  • In [year], [gene] mutations were first implicated in the pathogenesis of [disease name].

Classification

  • There is no established system for the classification of [disease name].

OR

  • [Disease name] may be classified according to [classification method] into [number] subtypes/groups:
    • [Group1]
    • [Group2]
    • [Group3]
    • [Group4]

OR

  • [Disease name] may be classified into [large number > 6] subtypes based on:
    • [Classification method 1]
    • [Classification method 2]
    • [Classification method 3]
  • [Disease name] may be classified into several subtypes based on:
    • [Classification method 1]
    • [Classification method 2]
    • [Classification method 3]

OR

  • Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.

OR

  • If the staging system involves specific and characteristic findings and features:
  • According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].

OR

  • The staging of [malignancy name] is based on the [staging system].

OR

  • There is no established system for the staging of [malignancy name].

Epidemiology and Demographics

Prevalence

  • The prevalence of Peutz-Jeghers syndrome is estimated to be 1 in 25000 to 300000

Age

  • Adolescent and early adulthood.

Gender

  • Males and females are equally affected.

Causes

Genetic Causes

  • [Disease name] is caused by a mutation in the [gene name] gene.

References